BiotechTV - News

Recently named CEO Serge Messerlian, who was previously CEO of Teon Therapeutics and President of Janssen Oncology, describes the platform behind this deal, which came with an upfront payment/investment of $13 million.

CEO David Venables describes Laverock's platform that repurposed miRNA to reprogram cells in a highly specific way. It's own lead programs will be in oncology and regenerative medicine.

Dr. Rich Ferrie gives BiotechTV a preview of the new facilities and describes how it is aimed for growing companies that have already achieved a series A or B. It has started at 37% occupancy on launch day.

CEO Adrian Gottschalk describes chromatin regulation at a high level, and walks us through the Lilly partnership targeting SMARCA2, and Foghorn's independent programs targeting CBP, EP300, and ARID1B.

She describes why such an analysis would be beneficial in analyzing clinical benefit for this type of condition - where the patient population is heterogenous in how they are affected by the disease. Plus, a description of Epicrispr's epigenome approach to science, and her personal relationship to facioscapulohumeral muscular dystrophy.

He describes the clinical data in FA cardiomyopathy that was announced this month, and explains how the company is preparing to begin a clinical trial for accelerated approval by early 2026. Plus, how we should expect more ACM data in 2025.

He describes how Metsera, which had its IPO two months ago, is aiming to develop a differentiated GLP-1 vs currently marketed products by having a lower dose and longer half-life. We discuss all the hot button issues in the obesity space today.

He describes the market potential of the company's HIF-2⍺, a target that has already been de-risked by a large pharma, why he believes being Fc silent will allow Arcus to succeed in TIGIT where others have failed, and a CD73 program that is enrolling very quickly in pancreatic cancer.

CSO John Connolly describes how recent new hires and a willingness to lead will expand PICI's already broad reach in cancer research circles. Plus, his take on what regulatory reforms could help U.S. competitiveness, and areas of research that excite him today.

Founder and CEO Nicole Paulk describes the process, which allows the public to invest as little as $100, and why she views the investors that come with it as an asset for her company.

CEO Rick Winningham describes the science behind ampreloxetine, and the rationale for developing it for patients with multiple system atrophy. A commercial stage company that already receives income from two therapies (YUPELRI and TRELEGY), Theravance Biopharma's future direction and focus will be determined by the outcome of this key trial.

CEO Josh Lehrer and CSO Ethan Weiss describe the biology of the target and highlight the topline data, which was first announced at #JPM25 . Plus, details on a new program targeting acromegaly.

Co-Founder & CEO Sek Kathiresan walks us through the data, which so far has showed a clean safety profile and an impressive ability to lower LDL by over 50% in patients with a genetic form of hypercholesterolemia.

Dr. Schlessinger descrbies how the new center is meant to speed up drug discovery work and enable Mount Sinai researchers to develop molecules that are more dynamic and with a higher success rate. It might also enable them to take drug development further than they traditionally have before.

They discusses takeaways from the conference, and comment on Beam, Korro, Wave, Intellia, Prime, Janux, Alto Nuero, Rapport, and YmAbs.

CFO David Nassif describes the unmet need that still exists today in HAE, and updates us on programs in both the acute and prophylactic settings.

He describes where this fits into the ROS1 space, and the data that has been derived for the filing. Plus, mIDH1, drug-drug-conjugates, and his take on the current environment in biotech.

He describes the 48 week data for the exon 53 DMD program, and discusses the company's plan to seek accelerated approval. Plus, guidance on when to expect clinical updates on other programs.

Brad Sitko describes how XOMA is able to do smaller deals than other larger investors in this space, and he gives examples of investments they have made. Plus how to help with the "zombie biotech" problem in some corners of the sector.

She describes how the mechanism of Haduvio differs from other programs in chronic cough, and covers the recent phase 2a RIVER data.

They discusses the macro and regulatory factors that have affected the sector so strongly, and comment on Wave, Korro, ProQr, Capricor, Trevi, and Kalvista.

He shares his take on biotech and discusses argenx, Immunovant, AnaptysBio, Apogee, Dianthus, and Viridian.

CEO Helen Matthews describes the types of medicines they are supporting for clinical trials (including Ambroxol and GLP-1s), and folding a few programs into a dynamic, international consortium.

Co-Founder and CEO Thomas Kledal describes the science behind this platform and program. Plus, how having access to donated kidneys is helping the company with its translational work.

CEO Jason Gardner describes Ampersand's platform that is designed to make medicines act at the site of disease. He also shares updates on partnerships with Pfizer and Pioneering Medicines, and highlights work in obesity, immuno-inflammation and immuno-oncology.